I received my dx of stage IV NSCLC adenocarcinoma in July, 2010. Primary tumor in RUL with mets in left lung, left pelvis and several ribs. A biopsy of lesion in left pelvis confirmed diagnosis and confirmed I was EGFR+
Tarceva was tried as 1st line treatment which provided me with a mixed response for nearly a year. Then, following rather significant progression (additional and enlarging mets in both lungs, mets throughout spine, neck of right femor, and liver), I was switched to Carbo/Alimta for four cycles, followed by once per month Alimta only maintenance for six months until a CT in late September revealed several tumors in lungs had grown larger (but still almost all in lungs are sub-centimeter) and tumor in liver had progress from 8mm to 2.3cm in 4 months. With that evidence of progression, chemo maintenance was halted and I am now searching for clinical trials.
A new biopsy was performed taking a sample from the lesion in my liver. That was sent to Caris for analysis and, according to the report recieved, mutational analysis yielded the following results:
Negative for a BRAF mutation
Positive for a p.L858R in exon 21 of EGFR
Positive for T790M in exon 20
Negative for a KRAS mutation
Indeterminate for PIK3CA
Testing for cMET with FISH showed amplification with a value of 5.91
ALK translocation absent
I have not found an abundance of trials that look like good choices for me. I live in SW Washington state (Vancouver, WA) and would be able to at least consider travel to study sites in or near Seattle, or, more preferably, Portland, Oregon. I have discovered trial NCT01348126 – Ganetespib (STA-9090) + Docetaxel in advanced NSCLC (GALAXY)
One of the available study sites is right here in Portland, OR so would be extremely convenient.
I am looking for, and will appreciate, any help available in selecting a suitable trial.